Roth Capital Forecasts Reduced Earnings for Nuvectis Pharma

Nuvectis Pharma, Inc. (NASDAQ:NVCT) – Equities researchers at Roth Capital lowered their Q1 2025 earnings per share estimates for Nuvectis Pharma in a research report issued on Tuesday, February 25th. Roth Capital analyst J. Aschoff now anticipates that the company will post earnings of ($0.28) per share for the quarter, down from their prior estimate of ($0.23). The consensus estimate for Nuvectis Pharma’s current full-year earnings is ($1.01) per share. Roth Capital also issued estimates for Nuvectis Pharma’s Q2 2025 earnings at ($0.26) EPS, Q3 2025 earnings at ($0.27) EPS, Q4 2025 earnings at ($0.27) EPS, FY2025 earnings at ($1.08) EPS, FY2026 earnings at ($1.12) EPS and FY2027 earnings at $1.33 EPS.

Nuvectis Pharma (NASDAQ:NVCT) last issued its earnings results on Tuesday, March 4th. The company reported ($0.36) EPS for the quarter, missing analysts’ consensus estimates of ($0.28) by ($0.08).

Separately, HC Wainwright decreased their price target on shares of Nuvectis Pharma from $21.00 to $11.00 and set a “buy” rating for the company in a research note on Tuesday.

Nuvectis Pharma Stock Performance

Shares of Nuvectis Pharma stock opened at $6.71 on Friday. Nuvectis Pharma has a 52 week low of $4.44 and a 52 week high of $12.10. The stock has a 50 day moving average price of $6.22 and a two-hundred day moving average price of $6.41. The stock has a market capitalization of $129.64 million, a PE ratio of -5.78 and a beta of 0.22.

Hedge Funds Weigh In On Nuvectis Pharma

A number of institutional investors and hedge funds have recently added to or reduced their stakes in NVCT. Baldwin Wealth Partners LLC MA boosted its holdings in Nuvectis Pharma by 104.4% in the 4th quarter. Baldwin Wealth Partners LLC MA now owns 355,961 shares of the company’s stock worth $1,926,000 after buying an additional 181,831 shares during the period. Marshall Wace LLP grew its position in shares of Nuvectis Pharma by 191.0% in the fourth quarter. Marshall Wace LLP now owns 124,571 shares of the company’s stock valued at $674,000 after purchasing an additional 81,757 shares in the last quarter. Iridian Asset Management LLC CT bought a new stake in shares of Nuvectis Pharma during the 3rd quarter valued at $348,000. Geode Capital Management LLC lifted its holdings in Nuvectis Pharma by 49.8% during the 3rd quarter. Geode Capital Management LLC now owns 79,716 shares of the company’s stock worth $501,000 after purchasing an additional 26,489 shares in the last quarter. Finally, Oppenheimer & Co. Inc. purchased a new position in Nuvectis Pharma during the 4th quarter valued at about $135,000. Institutional investors own 96.77% of the company’s stock.

Insider Buying and Selling

In other news, major shareholder Marlio Charles Mosseri acquired 240,000 shares of the firm’s stock in a transaction that occurred on Friday, February 7th. The stock was bought at an average price of $5.00 per share, with a total value of $1,200,000.00. Following the acquisition, the insider now owns 2,884,121 shares in the company, valued at $14,420,605. The trade was a 9.08 % increase in their position. The acquisition was disclosed in a document filed with the SEC, which is accessible through the SEC website. In the last quarter, insiders have purchased 261,500 shares of company stock valued at $1,300,825. 35.78% of the stock is owned by company insiders.

About Nuvectis Pharma

Nuvectis Pharma, Inc, a biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious unmet medical needs in oncology. The company's lead product candidate is NXP800, a novel small molecule that is in Phase 1b clinical trials for the treatment of patients with platinum-resistant, ARID1a-mutated ovarian carcinoma.